Is Bayer Stock a Buy?
Over the past five years, shares of Bayer (OTC: BAYRY) are down by 65%. This compares unfavorably to the S&P 500, which is up by 18% over the same period. Bayer's stock has also been hit much harder by the ongoing sell-off caused by the COVID-19 pandemic; the company's shares are down by 32% year to date, while the S&P 500 is down by 24%.
However, the past is the past, and Bayer could outpace the broader market from here on out -- which would make the company a buy, given that it's currently trading at just 7 times future earnings and its forward price-to-earnings growth (PEG) ratio is just 0.1. Those are certainly attractive valuation metrics, but does Bayer have the tools to perform much better than it did over the past five years?
Image source: Getty Images.
Source Fool.com
